Activation of the EGFR pathway was examined based on the phosphorylation of the EGFR (EGFR-p) molecule; however, treatment of PDX-B13 tumor with PAL, AFA, ERB, PAL+AFA, and PAL+ERB could reduce the EGFR phosphorylation level when compared with the negative control (DMSO), indicating that all the tested drugs could suppress the EGFR pathway by 70–90% (Figure 5). Here, ESR2 is linked to neoplasm.